⊘UBIC

June 24, 2014

UBIC's Advanced Forensic Tool Supports Third-Party Investigation

High-Level Analysis Support Solutions Service Delivering Results as Big Data Analysis Grows in Importance

TOKYO, June 24, 2014 (GLOBE NEWSWIRE) -- <u>UBIC</u>, Inc. (Nasdaq:UBIC) (TSE:2158), a leading provider of international litigation support and big-data analysis services, announced today the achievements of its new high-level analysis support solutions service for third-party investigation charged with investigating corporate fraud and other cases of inappropriate practices in Japan. <u>UBIC</u> is cited by reports issued by two major pharmaceutical manufacturers, Takeda Pharmaceutical Co. Ltd. and Novartis Pharma K.K., whose third-party investigations used UBIC's analysis support solutions, which take advantage of the company's evidentiary document analytics and review platform, Lit i View®.

The investigation results as described in Takeda's third-party investigation report published on June 20 show that the new analysis support service provides an efficient and effective alternative option to the human review of electronic data in ediscovery work.

Usually, third-party investigations which have been set up to investigate a fraud case, for example, would engage a digital forensic service vendor to identify and collect potential evidence from the corporation's electronic data stores and put a team of lawyers to work examining the selected data in more detail. This process requires a great deal of time, manpower and money. <u>UBIC</u>'s new service can substantially reduce the time, labor and cost of investigation by simplifying and speeding up this process. <u>UBIC</u> provides investigators with access to an artificial intelligence (AI)-based evidence analysis system, via the cloud, that can perform functions including personal network analysis and Asian-language keyword search very quickly and accurately. <u>UBIC</u> also provides services to train investigating lawyers to operate the system and to support analysis.

Novartis Pharma K.K.'s third-party investigation report, published on April 2, also includes findings that highlight the excellence of <u>UBIC</u>'s high-level analysis support solutions service.

These reports highlight the reliability of <u>UBIC</u>'s solutions service, as well as our technological prowess.

High-level analysis solutions are becoming increasingly essential not only in investigations by third-party investigation but also in criminal investigations by law enforcement authorities. As a pioneer of information analysis solutions using "behavior informatics" - which refers to the science of analyzing electronic data as a collection of thinking and behavior patterns of humans - <u>UBIC</u> will continue to pursue advancements in R&D and contribute to the creation of a better and safer society.

About UBIC

<u>UBIC</u>, Inc. (Nasdaq:UBIC) (TSE:2158) is a leading provider of e-discovery and digital forensic services for Asia and the world. <u>UBIC</u> has extensive experience working with electronically stored information composed in Chinese, Japanese and Korean (CJK) languages and utilizes that expertise for clients involved in cross-border litigation, corporate investigations, intellectual property disputes and much more. At the forefront of e-discovery innovation, <u>UBIC</u>'s proprietary Lit i View[®] platform is moving the industry from "fact discovery" to "future discovery" by allowing clients to analyze e-mail messages and digital communications found in big data to reveal patterns in human thought and behavior.

For more information about UBIC, contact us info@ubicna.com or visit http://www.ubicna.com.

CONTACT: Masatoshi Ohno

UBIC North America, Inc.

Email: masatoshi_ohno@ubic.co.jp

Sasha Hefler

UBIC North America, Inc.

Tel: (650) 868-2623

sasha_hefler@ubicna.com